Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.
04 Mar 2021
17 Feb 2021
Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
15 Feb 2021
The University of Oxford, along with three partner sites in the UK, has commenced the first trial to evaluate the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
05 Feb 2021
Johnson & Johnson’s subsidiary Janssen Biotech has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for its investigational single-dose Janssen Covid-19 vaccine candidate.
04 Feb 2021
GlaxoSmithKline has signed a €150m collaboration agreement with German global pharmaceutical company CureVac in a bid to jointly develop next-generation mRNA vaccines for Covid-19.
03 Feb 2021
Ocugen, a Pennsylvania-based pharmaceutical company, has signed an agreement with Bharat Biotech, an Indian pharma developer of COVAXIN, a Covid-19 vaccine, to distribute the vaccine in the US.
01 Feb 2021
AstraZeneca has secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.
27 Jan 2021
The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.
20 Jan 2021
Swiss pharma giant Novartis and British pharmaceuticals company GSK have teamed up to conduct scientific research linking genetic diversity in Africa and its potential impact on response to drug therapeutics.